Listed times are in Central European Summer Time (CEST)

REGISTRATION

Light refreshments will be served at 12:00

CONFERENCE WELCOME

Session 1: Unveiling the biology beneath the biomarkers: Mechanisms driving liquid biopsy signals

Chair: Ellen Heitzer

OPENING KEYNOTE LECTURE

Efrat Shema Weizmann Institute of Science, Israel

'Single-molecule epigenetic analysis of plasma-circulating nucleosomes for cancer diagnosis'

Q&A 13:40-13:55

Amin El-Heliebi Med Uni Graz, Austria

'Integrating liquid biopsy and spatial transcriptomics for understanding ctDNA release'

Q&A 14:15-14:25

Sangmi Lee Harvard Medical School, USA

Proferred Paper 1: 'Mechanistic interpretation of cfDNA fragmentation topography through joint deconvolution of fragmentation processes and tissue composition with cfVista'

Q&A 14:35-14:40

EXHIBITOR INTRODUCTIONS

COFFEE BREAK, EXHIBITION AND SOLO TRAVELLERS' MEET-UP

Remond Fijneman NKI, Netherlands

'Impact of tumor location and host factors on ctDNA shedding'

Q&A 15:40-15:50

Mischa Steketee Amsterdam UMC, Netherlands

Proferred Paper 2: 'Tumor-Informed Deconvolution of Circulating Extracellular Vesicle RNA in Large B Cell Lymphoma Patients Reveals On-treatment Tumor-Microenvironment Evolution'

Q&A 16:00-16:05

Proffered Paper 3

Q&A: 16:15-16:20

POSTER SPOTLIGHTS

INDUSTRY SYMPOSIUM - biomodal

PANEL DISCUSSION

'Where is liquid biopsy heading in the next 5–10 years? Clinical implementation, standardization and regulatory challenges'

WELCOME RECEPTION

POSTER DISCUSSION SESSION 1

Led by members of the Scientific Programme Committee

Listed times are in Central European Summer Time (CEST)

EARLY POSTER VIEWING

Chair: Claus Lindbjerg Andersen

INDUSTRY SPOTLIGHT - Ultima Genomics

Talk Title TBC

Session 2: Tracking the unseen: Liquid biopsies in advanced and metastatic cancer

Karen-Lise Garm Spindler Aarhus University, Denmark

'Using ctDNA for response evaluation in solid tumors – a paradigm shift in medical oncology?'

Q&A 9:20-9:30

Peter Ulz Medical University Graz, Austria

Proferred Paper 4: 'Landscape of somatic copy-number alterations in advanced breast, prostate and colorectal cancers by longitudinal shallow whole-genome sequencing of cell-free DNA'

Q&A 09:40-09:45

Ellen Heitzer Meduni Graz, Austria

'Signal vs Noise: The Reality of ctDNA in Advanced Disease'

Q&A 10:05-10:15

Irene Casanova VHIO, Spain

'EV-enhanced liquid biopsy for tumor dynamics in metastatic Prostate Cancer'

Q&A 10:35-10:45

COFFEE BREAK AND EXHIBITION

François Clément Bidard Institut Curie & UVSQ/Université Paris-Saclay, France

'Intercepting late resistance to therapy with ctDNA: ESR1 mutations and beyond'

Q&A 11:35-11:45

Galatea Kallergi University of Patras, Greece

Proferred Paper 5: 'Unraveling the Phenotypic Heterogeneity of Tumor-Derived Cells in the Bloodstream of Pancreatic Cancer Patients'

Q&A 11:55-12:00

POSTER SPOTLIGHTS

INDUSTRY SYMPOSIUM - Becton Dickinson

LUNCH

POSTER DISCUSSION SESSION 2

Led by members of the Scientific Programme Committee

Session 3: Frontiers in liquid biopsy technology: From fragmentomics to functional readouts

Chair: Nikolas Stoecklein

Mette Aaegebeck University of Copenhagen, Denmark

'Oncofetal Chondroitin Sulfate: A circulating biomarker on tumour-derived CTCs, EVs, and soluble proteoglycans'

Q&A 15:20-15:30

Proferred Paper 6

Q&A 15:40-15:45

Anton Fornies Marine IDIBAPS, Spain

Proferred Paper 7: 'Cell type signatures derived from cfDNA fragmentation profiles in patients with melanoma or benign melanocytic lesions'

Q&A 15:55-16:00

Nikolas H. Stoecklein University of Dusseldorf, Germany

'From Milliliters to Liters: Diagnostic Leukapheresis Enables High-Volume Liquid Biopsy for Rare CTC Detection'

Q&A 16:20-16:30

COFFEE BREAK AND EXHIBITION

An Hendrix Ghent University, Belgium

'Extracellular vesicle-based biomarkers: from technology towards biomedical application'

Q&A 17:20-17:30

Anders Jacobsen Skanderup Genome Institute of Singapore, Singapore

'Toward Scalable Tumor-Naïve ctDNA Quantification'

Q&A 17:50-18:00

PANEL DISCUSSION

'Publication strategies and the responsible use of AI in scientific writing'

Scheduled to end at 18:45

CONFERENCE DINNER (OPTIONAL TICKETED EVENT)

Listed times are in Central European Summer Time (CEST)

EARLY POSTER VIEWING

Chair: An Hendrix

INDUSTRY SPOTLIGHT - Particle Metrix

Talk Title TBC

Session 4: Liquid insights at the earliest stage: Transforming localised cancer detection and intervention

KEYNOTE LECTURE

Maximilian Diehn Stanford University, USA

'Analysis of cell-free RNA for cancer detection and characterization'

Q&A 09:30-09:45

Claus Lindbjerg Andersen Aarhus University, Denmark

'From Resection to Recurrence Prediction: The Role of Liquid Biopsy in CRC Management'

Q&A 10:05-10:15

Christopher Sng Institute of Cancer Research, UK

Proferred Paper 8: 'Augmenting circulating tumour DNA (ctDNA) recurrence prediction in resected colorectal cancer (CRC) through primary tumour genome sequencing'

Q&A 10:25-10:30

COFFEE BREAK AND EXHIBITION

Nickolas Papadopoulos John Hopkins Medicine, USA

'Quantification of disease burden in acute myeloid leukemia patients'

Q&A 11:20-11:30

Angela DeMichele Penn Medicine, USA

'ctDNA in the neoadjuvant and adjuvant management of breast cancer: the quest for clinical utility'

Q&A 11:50-12:00

SUMMARY AND CLOSE